Kent F. Hoskins

Kent F. Hoskins

Auto-generated profile, based on publicly available information

Kent F. Hoskins

Division of Hematology/Oncology, University of Illinois Chicago, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
KHKent F. Hoskins
Kent F. Hoskins
ODOana C. Danciu
Oana C. Danciu
NKNaomi Y. Ko
Naomi Y. Ko
GCGregory S. Calip
Gregory S. Calip
Prognostic gene expression profiles are firmly established as an integral component of treatment planning for women with early-stage, estrogen receptor (ER)–positive, ERBB2 (eg, formerly HER2 or HER2/neu)–negative breast cancer. Endorsement of these genomic biomarkers in treatment guidelines1-3 and their widespread adoption in clinical practice4,5 are the result of concerted efforts to establish the clinical validity and utility of these tests with retrospective5-10 and prospective11-15 validation studies. The most commonly ordered genomic assay for obtaining prognostic information on the risk of distant recurrence and for predicting the likelihood of benefit from adjuvant chemotherapy in women with ER-positive breast cancer is the 21-gene recurrence score (RS) on the Oncotype DX Breast Recurrence Score test.4 The gene set included in the expression profile and the algorithm for determining the RS were developed using tumors from a subset of participants enrolled in the National Surgical Adjuvant Breast and Bowel Project B-20 trial5,16 and from single-institution case series.17 A key principle of biomarker development is that the cohorts used for discovery and validation should be representative of the populations targeted for clinical application of the biomarker.18 The racial/ethnic distribution of the tumors used to develop the RS was not reported, but overall only 6% of B-20 participants were Black.16 The landmark study6 validating the prognostic accuracy of the RS in a subset of participants from the National Surgical Adjuvant Breast and Bowel Project B-14 trial included 5% Black women. Underrepresentation of women from racial/ethnic minority groups in the development and validation of the RS raises questions about the prognostic accuracy of the Oncotype DX Breast Recurrence Score test in populations other than non-Hispanic White people. This issue is especially relevant in light of persistent racial disparities in survival among Black women with ER-positive breast cancer.19

1 April 2023 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
KHKent F. Hoskins
Kent F. Hoskins
GCGregory S. Calip
Gregory S. Calip
HHHsiao-Ching Huang
Hsiao-Ching Huang
AIAbiola Ibraheem
Abiola Ibraheem
ODOana C. Danciu
Oana C. Danciu
GRGarth H. Rauscher
Garth H. Rauscher
Importance: Black women with hormone receptor–positive breast cancer experience the greatest racial disparity in survival of all breast cancer subtypes. The relative contributions of social determinants of health and tumor biology to this disparity are uncertain.Objective: To determine the proportion of the Black-White disparity in breast cancer survival from estrogen receptor (ER)-positive, axillary node-negative breast cancer that is associated with adverse social determinants and high-risk tumor biology.Design, Setting, and Participants: A retrospective mediation analysis of factors associated with the racial disparity in breast cancer death for cases diagnosed between 2004 and 2015 with follow-up through 2016 was carried out using the Surveillance, Epidemiology, and End Results (SEER) Oncotype registry. The study included women in the SEER-18 registry who were aged 18 years or older at diagnosis of a first primary invasive breast cancer tumor that was axillary node-negative and ER-positive, who were Black (Black), non-Hispanic White (White), and for whom the 21-gene breast recurrence score was available. Data analysis took place between March 4, 2021, and November 15, 2022.Exposures: Census tract socioeconomic disadvantage, insurance status, tumor characteristics including the recurrence score, and treatment variables.Main Outcomes and Measures: Death due to breast cancer.Results: The analysis with 60 137 women (mean [IQR] age 58.1 [50-66] years) included 5648 (9.4%) Black women and 54 489 (90.6%) White women. With a median (IQR) follow-up time of 56 (32-86) months, the age-adjusted hazard ratio (HR) for breast cancer death among Black compared with White women was 1.82 (95% CI, 1.51-2.20). Neighborhood disadvantage and insurance status together mediated 19% of the disparity (mediated HR, 1.62; 95% CI, 1.31-2.00; P < .001) and tumor biological characteristics mediated 20% (mediated HR, 1.56; 95% CI, 1.28-1.90; P < .001). A fully adjusted model that included all covariates accounted for 44% of the racial disparity (mediated HR, 1.38; 95% CI, 1.11-1.71; P < .001). Neighborhood disadvantage mediated 8% of the racial difference in the probability of a high-risk recurrence score (P = .02).Conclusions and Relevance: In this study, racial differences in social determinants of health and indicators of aggressive tumor biology including a genomic biomarker were equally associated with the survival disparity in early-stage, ER-positive breast cancer among US women. Future research should examine more comprehensive measures of socioecological disadvantage, molecular mechanisms underlying aggressive tumor biology among Black women, and the role of ancestry-related genetic variants.

10 September 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
CSCandice Schwartz
Candice Schwartz
ICIfeanyi Beverly Chukwudozie
Ifeanyi Beverly Chukwudozie
STSilvia Tejeda
Silvia Tejeda
GVGanga Vijayasiri
Ganga Vijayasiri
IAIvy Abraham
Ivy Abraham
KHKent F. Hoskins
Kent F. Hoskins
Widespread implementation of screening mammography contributed to the decrease in breast cancer mortality in the US over the past 30 years,1 but not all women benefited equally. Racial disparities in breast cancer mortality emerged as routine screening mammography became the standard of care, and more than 3 decades later the breast cancer mortality rate for Black women remains 40% higher compared with non-Hispanic White women.2 Racial stratification in the US produces inequities in health care and health outcomes through multilevel social determinants of health.3 Black women in the US historically have had lower rates of screening mammography,4 which leads to a higher proportion of late-stage diagnoses and lower survival rates.5 Data have shown a narrowing of the racial gap from 1987 to 2015, but lower screening rates persist among women of racial and ethnic minority groups with socioeconomic disadvantage.6

9 July 2021 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CYConnie H. Yan
Connie H. Yan
CCChandler Coleman
Chandler Coleman
NNNadia A. Nabulsi
Nadia A. Nabulsi
BCBrian C.-H. Chiu
Brian C.-H. Chiu
NKNaomi Y. Ko
Naomi Y. Ko
GCGregory Sampang Calip
Gregory Sampang Calip

12 May 2015 in Journal of the Academy of Nutrition and Dietetics
Verified
Journal Article
Closed access
PDF file
PSPatricia Sheean
Patricia Sheean
CKChristopher Kabir
Christopher Kabir
RRRuta Rao
Ruta Rao
KHKent Hoskins
Kent Hoskins
MSMelinda Stolley
Melinda Stolley

15 September 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
KHKent F. Hoskins
Kent F. Hoskins
STSilvia Tejeda
Silvia Tejeda
GVGanga Vijayasiri
Ganga Vijayasiri
ICIfeanyi Beverly Chukwudozie
Ifeanyi Beverly Chukwudozie
MRMylene H. Remo
Mylene H. Remo
RWRichard B. Warnecke
Richard B. Warnecke